The internet has decided berberine is Nature's Ozempic. In this episode, the hosts unpack Dr Luke Iggulden's research-led clinical analysis of that claim, and what they find is considerably more nuanced than the TikTok consensus.

Dr Luke's blog pulls no punches. Ozempic works. Semaglutide is effective. But when you put the side effect profiles side by side and apply the foundational principle of medicine, first do no harm, the case for berberine as a first-line metabolic tool becomes hard to argue against.

This episode traces the pharmacology of berberine from the ground up: its origins as a benzylisoquinoline alkaloid found in plants like Berberis vulgaris, Hydrastis canadensis, and Phellodendron amurense; its clinical use as a broad-spectrum GIT microbiome modulator; and its activation of AMPK, the master energy sensor of the cell, with downstream effects on insulin sensitivity, lipid oxidation, and glucose regulation that mirror Ozempic's GLP-1 pathway in all the ways that matter for most patients.

The hosts also dig into one of the more fascinating pharmacokinetic observations in the blog: berberine's notoriously poor GIT absorption actually increases in obese individuals, meaning those who need it most absorb it best.

The conclusion is not that pharmaceuticals have no place. It is that for the majority of patients seeking metabolic support, the risk-benefit analysis falls clearly on the side of the plant.

Read the full clinical breakdown at precisionnaturalmedicine.com.au/post/natures-ozempic